Bio, Inc.’s US$200 Million Series A Financing

Wilson Sonsini Goodrich & Rosati advised the leading investors on the deal.

D3 Bio, Inc., a global biotechnology company, announced that it had entered into definitive agreements with respect to its US$200 million Series A financing led by Boyu Capital, Matrix Partners China, Sequoia Capital China, the corporate venture fund of WuXi AppTec, and certain other investors.

D3 Bio is a global biotechnology company developing and commercializing paradigm-shifting precision medicines to improve or replace existing oncology and immunology standard-of-care treatments that fail to or do not fully meet significant patient needs. D3 Bio collaborates with world-class partners across many geographic areas, integrating deep clinical and market insights about the healthcare treatment landscape with disruptive science and technological development through a progressive, iterative cycle of development to discovery and back to development.

Wilson Sonsini Goodrich & Rosati acted as legal counsel to Boyu Capital, Matrix Partners China, Sequoia Capital China, and the corporate venture fund of WuXi AppTec in the transaction. The Wilson Sonsini team was led by partners Weiheng Chen (Picture), Jie Zhu, and Barry Taylor, and included Jill Sheng, Leo Zhou, Tingjie Li, Yiwen Feng, and Jingyi Yuan.

Involved fees earner: Weiheng Chen – Wilson Sonsini Goodrich & Rosati; Jill Sheng – Wilson Sonsini Goodrich & Rosati; Barry Taylor – Wilson Sonsini Goodrich & Rosati; TJ Tingjie Li – Wilson Sonsini Goodrich & Rosati; Jingyi Yuan – Wilson Sonsini Goodrich & Rosati; Leo Zhou – Wilson Sonsini Goodrich & Rosati; Jie Zhu – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: boyu capital investment management co ltd; Matrix Partners; Sequoia Capital China; WuXi AppTec Co. Ltd.;

Author: Michael Patrini